Articles
Pelage Pharmaceuticals has announced topline results from its Phase 2a trial of PP405, a new topical aimed at reactivating dormant hair follicle stem cells to treat androgenic alopecia (AGA). While the data show promise for a regenerative approach, there are important limitations and open questions to keep in mind. The Study The Phase 2a study…
More news is coming out of Kintor Pharma this month. Kintor Pharma (HKEX: 9939) has announced that its observational study evaluating the combination of KX-826 and minoxidil for the treatment of androgenetic alopecia (AGA) in adult males in China has successfully reached its primary endpoint. This marks another milestone in the development of KX-826, following…
Inmagene Biopharmaceuticals Announces Positive Phase 2a Trial Results for IMG-007 in Alopecia Areata
Inmagene Biopharmaceuticals, a clinical-stage company focused on immunological and inflammatory diseases, has announced topline results from its Phase 2a clinical study of IMG-007 in patients with severe alopecia areata. What Is Inmagene Biopharmaceuticals? Inmagene Biopharmaceuticals was founded to advance therapies targeting immune-mediated and inflammatory conditions. The company develops novel monoclonal antibodies and small molecules, aiming…
Atticus Pharma, a clinical-stage biopharmaceutical company specializing in immunodermatology treatments, has announced the initiation of its first human clinical trial of ATC-002 for androgenic alopecia. What is Atticus Pharma? Atticus Pharma was founded in 2024 to develop pharmaceutical applications of its proprietary Z-pod® technology, a sustained-release drug delivery platform designed to improve treatment outcomes in…
Earlier this month, Kintor announced that its long-term Phase 3 safety trial of 0.5% KX-826 had reached its primary endpoint with statistically significant and clinically meaningful outcomes. This comes after a history of multiple trials, some with mixed results. The Trial This trial was a multi-center (16 centers), open-label study taking place over 52 weeks. …
Q32 Bio presented results from their SIGNAL-AA earlier this month at the American Academy of Dermatology (AAD) 2025 meeting for their novel alopecia areata (AA) therapy bempikibart. What is Bempikibart? Bempikibart is an experimental monoclonal antibody drug that targets two specific molecules in the body: the alpha receptor of interleukin-7 and the thymic stromal lymphopoietin…
HCW Biologics has received FDA clearance to start a first-in-human safety trial for their potential alopecia areata treatment, HCW9302. Who Are HCW Biologics? HCW Biologics Inc. is a clinical-stage biopharmaceutical company based in Miramar, Florida. The company focuses on developing immunotherapies targeting chronic inflammation in age-related diseases like cancer, autoimmune disorders, and neurodegenerative conditions. The…
After a slow and disappointing winter season in 2024, we start the year with some positive news in the androgenic alopecia space. Eirion Therapeutics, a clinical-stage biopharmaceutical company with oral and topical androgenic alopecia treatments in the pipeline, has announced results from their 4-week androgenic alopecia trial of topical ET-02. What Is ET-02? We don’t…
Sun Pharma revealed data at the 2024 Fall Clinical Dermatology Conference (held between October 24th – 27th, 2024, in Las Vegas, Nevada) regarding the efficacy of LEQSELVI (deuruxolitinib), its treatment for alopecia areata (AA). The data includes collated results from open-label extension studies that have monitored LEQSELVI used for up to 68 weeks. Improvements were…
Kintor Pharmaceutical has recently announced the enrollment of its first participant in its “Pivotal Clinical Trial”. This is a Phase 2/3 trial in which men with androgenic alopecia will be treated with either vehicle control, 0.5%, or 1% topical for 24 weeks. The trial will be conducted in China, with 222 patients enrolled in each…